Investments in equity securities (Details Narrative) - USD ($) |
12 Months Ended | |||
|---|---|---|---|---|
Sep. 11, 2025 |
Dec. 22, 2023 |
Apr. 11, 2023 |
Dec. 31, 2025 |
|
| Restructuring Cost and Reserve [Line Items] | ||||
| Impairment loss | $ 5,141,849 | |||
| Share Purchase Agreement [Member] | ||||
| Restructuring Cost and Reserve [Line Items] | ||||
| Interest | 250,000 | |||
| Impairment loss | $ 1,900,000 | |||
| One Up Group, LLC [Member] | ||||
| Restructuring Cost and Reserve [Line Items] | ||||
| Investment interest acquired percentage | 18.62% | |||
| Investment acquired fair value | $ 2,200,000 | $ 3,200,000 | ||
| BackBone Labs Inc [Member] | ||||
| Restructuring Cost and Reserve [Line Items] | ||||
| Investment acquired fair value | $ 100,000 |
| X | ||||||||||
- Definition Percentage of voting equity interest acquired in business combination. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Fair value at acquisition date of equity interest in acquiree held by acquirer immediately before acquisition date in business combination achieved in stages. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Interest and debt related expenses associated with nonoperating financing activities of the entity. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|